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Abundance of pseudo splice sites in introns can potentially
give rise to innumerable pseudoexons, outnumbering
the real ones. Nonetheless, these are efficiently ignored
by the splicing machinery, a process yet to be under-
stood completely. Although numerous 50 splice site-like
sequences functioning as splicing silencers have been
found to be enriched in predicted human pseudoexons,
the lack of active pseudoexons pose a fundamental chal-
lenge to how these U1snRNP-binding sites function in
splicing inhibition. Here, we address this issue by focusing
on a previously described pathological ATM pseudoexon
whose inhibition is mediated by U1snRNP binding at
intronic splicing processing element (ISPE), composed of
a consensus donor splice site. Spliceosomal complex
assembly demonstrates inefficient A complex formation
when ISPE is intact, implying U1snRNP-mediated unpro-
ductive U2snRNP recruitment. Furthermore, interaction of
SF2/ASF with its motif seems to be dependent on RNA
structure and U1snRNP interaction. Our results suggest a
complex combinatorial interplay of RNA structure and
trans-acting factors in determining the splicing outcome
and contribute to understanding the intronic splicing code
for the ATM pseudoexon.
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Introduction
Deciphering the ‘splicing code’ (Fu, 2004; Wang and Cooper,
2007) is taking considerably longer than the elucidation of the
genetic code, which can be well attributed to the very
degenerate and extended nature of the splicing code.
Although each amino acid can be accounted for by a few
sequences with moderate degeneration, the splicing code
relies on a couple of common dinucleotide sequences
(GU/AG) and a vast array of highly degenerated signals that
act in a complex combinatorial way (Smith and Valcarcel,
2000; Han et al, 2005; Hertel, 2008). The initial clues for the
‘splicing code’ started with the sequencing of the early genes
(globins, ovalbumin) (Breathnach et al, 1978; Efstratiadis
et al, 1980) but the complexity became very obvious with
the discovery of alternative splicing of cellular genes such as
calcitonin (Amara et al, 1982) or fibronectin (Kornblihtt et al,
1984; Vibe-Pedersen et al, 1984). Surprisingly, the early
observation that exonic sequences were involved in the
definition of alternative splicing exons (Mardon et al, 1987)
went unnoticed for 45 years. These exonic sequences when
further mapped revealed an extended array of short signals
(Caputi et al, 1994). The fact that these sequences overlap
with the genetic code poses an intriguing evolutionary puzzle
(Xing and Lee, 2006). Since the early 1990s, a strong focus
has been placed on exonic and nearby intronic sequences as
the core of most attempts to elucidate the splicing code
(Wang and Burge, 2008; Wang et al, 2008). The reason for
this focus being that accurate pre-mRNA splicing is essential
for proper gene expression, and derangements of this process
accounts for about one fifth of inherited diseases (Solis et al,
2008; Cooper et al, 2009; Tazi et al, 2009).
In the splicing process, from the transcribed pre-mRNA
molecule, the introns must be spliced out and the exons
correctly ligated with each other to obtain the mature mRNA.
Intron removal is carried out by the spliceosome, a multi-
component enzymatic complex formed stepwise by the or-
dered interaction of UsnRNPs and non-snRNP proteins on
consensus sequences, known as 50 splice site (50ss) and
30 splice site (30ss), that define the intron/exon boundaries
(Nilsen, 2003; Chen et al, 2007; Matlin and Moore, 2007;
Wahl et al, 2009). The basic steps in spliceosome assembly
have been known since many years. In general, spliceosome
assembly is initiated by the interaction of the U1snRNP with
the 50ss, forming the E complex (Mount et al, 1983; Seraphin
and Rosbash, 1989). The latter also contains the 17S
U2snRNP, which at this stage associates via a non-base
pairing interaction (Das et al, 2000). In a subsequent ATP-
dependent step, the U2snRNA base pairs with the branch site
of the pre-mRNA, leading to stable association of U2snRNP
and formation of the A complex or prespliceosome (Konarska
and Sharp, 1987). Finally, the U4/U6.U5 tri-snRNP complex
binds generating the B complex, and after a major conforma-
tional change the C complex is formed (Will et al, 2002).
The fidelity of this process is severely challenged especially
in vertebrate genes, where small exons are interspersed
within multiple introns ranging from several hundred to
more than one hundred thousand nucleotides. As a result,
gene architecture has been recognized as a major influencing
factor of the splicing process (Fox-Walsh et al, 2005; Baralle
et al, 2006). Besides the gene architecture, an additional
complexity is represented by the observation that introns
contain many sequences that match the consensus 50ss and
30ss motifs as well as authentic sites and contain splicing
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regulatory sequences that would enhance their inclusion in
the mRNA, yet are virtually never used in splicing (Cote et al,
2001). In keeping with this, in silico searches show that these
sequences (also known as ‘pseudoexons’) are usually very
abundant in the introns of most genes (with this term we
refer to any nucleotide (nt) sequence between 50 and
2–300 nt in length with apparently viable 50ss, 30ss, and
branch sites at either end) (Sun and Chasin, 2000). The
ability of the splicing machinery to reliably distinguish real
exons, that, in some cases are numerically outnumbered by
an order of magnitude by pseudoexons is of paramount
importance, especially considering that pseudoexon inclusion
has been increasingly associated with occurrence of human
disease (Buratti et al, 2006). Normally, exclusion of many of
these aberrant pseudoexon sequences is achieved by the
presence of intrinsic defects in their composition (Sun and
Chasin, 2000), by the enrichment of silencer elements
(Fairbrother and Chasin, 2000; Sironi et al, 2004; Zhang
and Chasin, 2004), or by the formation of inhibiting RNA
secondary structures (Zhang et al, 2005).
In humans, among the exonic splicing silencer elements
found to be enriched in predicted pseudoexons, intriguingly
there are sequence elements bearing strong resemblance to
positions þ 1 through þ 6 of the human 50ss consensus
sequence (/GTRAGT), where the splice junction is indicated
by / and R indicates A or G (Wang et al, 2004). Functional
splicing assays using minigenes showed these 50ss-like
sequences as having silencer activity as well as being recog-
nized as 50ss. However, there is no clear mechanism and very
little is known regarding how these intronic 50ss-like
sequences sometimes inhibit pseudoexon splicing, whereas
in other cases are used as viable donor sites.
In this work, we have addressed this issue by experimen-
tally focusing on an earlier identified pathological pseudo-
exon splicing event between exon 20 and 21 of the ATM gene
whose exclusion is mediated by U1snRNP-binding site within
its sequence (Pagani et al, 2002). Using this model, we have
tried to understand the mechanism of U1snRNP-mediated
splicing inhibition by analysing in-depth the spliceosomal
complex assembly on the inactive (ATM WT) and active
(ATMD) pseudoexon sequences. We have also observed
that a binding site for positive splicing factor SF2/ASF is
present both in ATM WT and ATMD pseudoexons, but is
available for productive interaction only in the case of the
active ATMD pseudoexon that does not bind U1snRNP. We
additionally show that this availability for interaction is
dependent on RNA secondary structure for the display of
the protein-binding sequence. These observations have al-
lowed us to develop a model of ATM pseudoexon inhibition
that highlights the complexity of even seemingly simple
splicing decisions. As similar mechanisms are probably
operating in normal exons and introns, they should be
taken into consideration when constructing splicing code
models. In fact, until now all such models have focused on
exonic sequences and mainly considered linear sequence
parameters.
Results
Earlier, we have described the inclusion of a 65-nt long
pseudoexon between ATM exons 20 and 21 in a patient
affected by ataxia-telengiectasia (Pagani et al, 2002). This
pseudoexon activation event consisted of a 4-nt deletion
(GTAA) that occurred within a high-affinity U1snRNP-binding
site acting as an internal exonic splicing repressor (Figure 1A).
This region was termed intronic splicing processing element
(ISPE) (Pagani et al, 2002; Lewandowska et al, 2005). More
recently, we have demonstrated that the donor splice site
usage in this pseudoexon is also highly influenced by local
RNA secondary structure constraints (Buratti et al, 2007).
In this work, we have attempted to clarify the unusual
function of U1snRNP binding to the ATM WT sequence that
determines pseudoexon inhibition. First of all, to test whether
the inhibitory effect mediated through the ISPE could be
attributed to specific functional properties of U1snRNP or to
any other massive macromolecular complex of similar size,
we placed an U11snRNP-binding site in this position
(Figure 1B). As shown in Figure 1B, almost no pseudoexon
inclusion could be detected during the processing of the
ATMD U11RNA when compared with the ATMD pseudoexon.
In the U11 variant, in fact, the low level of pseudoexon
inclusion still observed can probably be attributed to the
lower concentration of U11snRNP (1/100th) with respect to
U1snRNP in Hela nuclear extracts (Pessa et al, 2008).
To better understand at which stage of the splicing process
U1snRNP is acting, it was decided to analyse spliceosomal
complex assembly on the ATM WT and ATMD pseudoexon
RNAs.
Spliceosomal complex assembly on ATM WT
and ATMD RNAs
To achieve this, we assembled spliceosomal complexes on a
biexonic substrate derived from the PY7 minigene. In these
constructs, the Exon 2 of a-tropomysin was present upstream
to the ATM WT and ATMD pseudoexon sequences that also
contained the downstream 50ss (Figure 2A). Spliceosome
complexes on these RNAs were then assembled in Hela
nuclear extract under splicing conditions and after heparin
treatment, splicing complexes were separated on native poly-
acrylamide gels. Interestingly, the intron-defined complexes
assembled on the ATM WT substrate showed an inefficient/
strongly reduced spliceosomal A complex formation (com-
pare lanes 2 and 5, Figure 2B) but not so in the ATMD
substrate. As the extent of ATP-dependent complex A forma-
tion reflects stable binding of U2snRNP on to the 30ss region,
this result suggested an inefficient recruitment of U2snRNP to
the ATM WT 30ss. As expected from these results, in vitro
splicing of these biexonic constructs demonstrated that the
spliceosomal complexes assembled across the EX2-ATM WT
construct resulted in no intron processing (Figure 2C, lanes
1–2), whereas this occurred in the case of the EX2-ATMD
RNA (Figure 2C, lanes 3–4).
To confirm these differences further, spliceosomal com-
plexes assembled on single exon substrates derived from the
ATM WT and ATMD sequences were analysed in vitro. Single
exon constructs of ATM WT and ATMD RNAs were used
carrying the upstream 30ss, the polypyrimidine/predicted
branch point (BP) sequences, 20 nt (named AS, as the an-
choring site) upstream to the BP, and the downstream 50ss
(Figure 2D). Under similar splicing condition used in
Figure 2B, this analysis showed that complexes were formed
both on the WT and D RNAs and that these complexes
assembled with near equal efficiencies at 5 min (compare
lanes 5 and 12, Figure 2E). We termed these ATP-dependent
Function of U1snRNP in inhibition of ATM pseudoexon splicing
A Dhir et al
The EMBO Journal VOL 29 | NO 4 | 2010 &2010 European Molecular Biology Organization750
complexes as A-like exon complexes. Interestingly, at longer
incubation periods of 10 min, the A-like exon complex on the
WT substrate seemed to dissociate or fall apart pointing
towards the unproductive nature of this complex. On the
other hand, the one assembled on the ATMD RNA was still
stable at this time point (compare lanes 6 and 13, Figure 2E).
Formation of these complexes was dependent on ATP and
U2snRNP (data not shown). Furthermore, the long-term
stability of the A-like complex in the ATMD RNA with respect
to the ATM WT RNA (in the absence of additional oligos) was
confirmed up to a 30-min incubation time (Supplementary
Figure S1B). The approximately three-fold difference in the
relative intensity of A-like complex between WT and
D appears at longer incubation of 30 min, suggested that
U2snRNP might be engaged in a unstable unproductive
binding at the 30ss of the WT substrate.
To address the question of whether these A-like exon
complexes could be functional or not, a 50ss RNA oligo ‘in-
trans’ was added at two separate time points of 5 and 10 min
to each substrate, as described earlier (Konforti and
Konarska, 1995). Each of the splicing reactions was then
incubated further for an additional 5 and 8 min (Figure 2E).
Gel analysis showed that in the presence of the 50ss RNA
oligo, the A-like exon complex formed on the ATMD RNA
could progress well to a B-like complex (lanes 14–17,
Figure 2E), whereas it could not do so as efficiently in the
case of the ATM WT RNA (lanes 7–10, Figure 2E). A control
oligo did not have any effect on B-like complex formation
(Supplementary Figure S1A).
Taken together, these observations on both biexonic as well
as single exon substrates highlight intrinsic differences be-
tween ATM WTand ATMD A/A-like complex formation. In this
respect, therefore, the reduced ability of A-like to B-like
progression observed in ATM WTseems to be the consequence
of an inefficient A-like complex in ATM WT (Figure 2E).
U2snRNP association with ATM WT and ATMD RNAs
As the A-like exon complex formed on ATM WT and ATMD
RNAs assembled with almost equal efficiencies at 5 min
(Figure 2E, lanes 5 and 12), it was decided to compare their
UsnRNP composition. To do this, these complexes were
purified taking advantage of an MS2 RNA hairpin-tagged
version of the ATM WT and ATMD RNAs as described earlier
(Deckert et al, 2006) (Figure 2D). We sought to compare the
relative binding stabilities of these UsnRNP to high-salt
washings. To achieve this, the WT and D A-like exon com-
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Figure 1 ATM pre-mRNA splicing of exon 20 and exon 21 and effect on U11snRNP binding as opposed to U1snRNP in the ATM WT sequence.
(A) Exons 20 and 21 are shown with light grey boxes, whereas the ATMD pseudoexon with black. Introns are depicted with a straight line. ‘ag’
and ‘gc’ represent the intronic splice sites flanking the pseudoexon. In normal splicing, the ISPE sequence is present and can bind an U1snRNP
molecule at this position. In the A-T patient, deletion of a GTAA sequence in the ISPE abrogates U1snRNP binding and activates inclusion of the
ATMD pseudoexon. Introduction of an U11snRNP-binding site restores inhibition. (B) Schematic representations of the binding positions of
U1snRNP and of U11snRNP on the ATM WTand ATMD U11 pseudoexons, respectively (the sequences are shown with bold underlined letters).
The sequence of the pseudoexon is shown with capital letters whereas splice sites are shown with underlined small bold letters. In vitro splicing
and RT–PCR analysis of the ATMD, ATMD U11, and ATM WT substrates in PY7 minigenes are shown. The scheme of the spliced and unspliced
substrates is shown on the right.
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plexes were bound to amylose beads and then washed with
250 mM NaCl. Silver stain of the resulting gels showed
stronger signal for U1snRNA in the ATM WT lane as com-
pared with ATMD lane, an observation consistent with the
fact that the ATM WT pseudoexon has two U1snRNP-binding
sites, one at ISPE and the other at the gc 50ss. Importantly,
and also consistent with the defective A-like exon complex,
ATM WT RNA showed a substantially reduced signal for the
U2snRNA as compared with the ATMD RNA (Figure 3).
Unstable U2snRNP recruitment in ATM WTcan also be better
appreciated by observing the ratio of the signal for U1snRNA
and U2snRNA (Figure 3). These results allowed us to con-
clude that U2snRNP is unstably associated with the 30ss
region of the ATM WT RNA as compared with ATMD
in the A-like exon complexes. It is interesting to point out
that although the A-like complexes are formed with almost
equal efficiency at 5 min time point (at which point UsnRNPs
are analysed), the observed differences for the U2snRNP
recruitment under high-salt washings clearly highlight the
intrinsic differences in the A-like complexes of ATM WT and
D, that become apparent at longer incubations (Figure 2E;
Supplementary Figure S1B).
Mapping of the SF2/ASF-binding site in the ATMD
sequence
To identify important splicing factors binding to the ATM
pseudoexon sequence beside the already identified U1snRNP,
we used an affinity pull-down assay protocol (Buratti et al,
2004a). The coomassie gel in Figure 4B (left panel) shows the
pull-down profiles of full-length ATM WT and ATMD con-
structs. As shown in this figure, clear differences could only
be detected (as determined by mass-spec analysis) at the
level of the U1snRNP subunits. These differences were con-
firmed by western blot analysis (Figure 4B, right panel).
At the same time, we also probed the gel for common splicing
factors (i.e. hnRNP A1 and SF2/ASF). In these cases, no
binding differences could be seen for hnRNP A1 but, rather
unexpectedly, they were detected for SF2/ASF. Interestingly,
SF2/ASF was also the only SR protein that could bind to the
ATMD construct, as determined using immunoprecipitation
analysis (Supplementary Figure S2). To better map the SF2/
ASF-binding site, we then repeated the pull-down analysis
using shorter RNA sequences. The pseudoexon sequence was
then divided in two halves for both ATM WT and ATMD to
obtain the three following synthetic RNAs: ATMWT 1–45,
ATMD 1–45, and ATM 32–65 RNA (Figure 4A). Pull-down
and Coomassie stain from these RNAs detected numerous
protein-binding profiles. Not many differences were observed
for the ATM WT 1–45 and ATMD 1–45 except for the
additional U1-associated proteins. On the other hand, the
ATM 32–65 RNA was found to bind specifically to SF2/ASF.
Mass-spec analysis also identified several proteins such as
hnRNP D-like, Septins, and FUBP that were preferentially
bound to this sequence (Figure 4C). However, as no clear
EX2-ATMWT EX2-ATMΔ
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Figure 2 Assembly of the spliceosomal complexes on ATM WTand ATMD pseudo exon substrates. (A) Scheme of the biexonic construct used
for assembly of cross-intron spliceosomal complexes upstream to the ATM pseudoexon. (B) Spliceosomal complex assembly at different
time-points on the ATM WT and D biexonic substrates. The positions of the splicing complexes are shown on the left. (C) In vitro splicing and
RT–PCR analyses of the ATM WT and ATMD biexonic constructs. (D) Scheme of the ATM WT and ATMD single exon substrates used for the
assembly of spliceosomal complexes. The 30 ends are tagged with 3 MS2 repeats. (E) Spliceosomal complex assembly at different time points
across both ATM WT and ATMD single exon substrates either in the absence or presence of the 50ssRNA oligo ‘in-trans’.
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differences in this region could be detected in the pull down
using the whole pseudoexon sequences, their significance
remains to be tested.
To better map the SF2/ASF-binding site on the 32–65
sequence, we then incubated the entire ATMD RNA with a
series of 12-mer antisense DNA oligos complementary to the
different regions of the 32–65 RNA (Figure 5A). In this
experiment, we observed a significantly diminished IP signal
only in the presence of the 56 oligo, suggesting that the SF2/
ASF-binding site is placed in the 47–66 regions, narrowing
down the putative binding sequence to ‘CGAAGGC’
(Figure 5B).
To demonstrate the functional involvement of SF2/ASF in
ATMD pseudoexon splicing, affinity depletion of SF2/ASF
was performed from the nuclear extract by incubating it
with a short GAAGAAGAC RNA bound to agarose beads.
This sequence, from the EDA exon, has been previously
shown to be specific binding site for SF2/ASF and to some
extent for other SR proteins (Buratti et al, 2004b). The
depletion of SF2/ASF from the nuclear extract was confirmed
by western blot (Figure 5C, lower panels). In keeping with
expectations, in vitro splicing of the ATMD RNA in this
depleted extract showed complete pseudoexon exclusion
(Figure 5C, lane 3) compared with a mock-depleted nuclear
extract (Figure 5C, lane 4). In parallel, we also performed an
in vitro overexpression experiment by adding recombinant
SF2/ASF into the nuclear extract. Under dilute conditions, the
pseudoexon spliced poorly (lane 1, Figure 5D). However,
addition of increasing amounts of recombinant SF2/ASF led
to increased splicing of the ATMD pseudoexon in a linear
manner (lanes 2–3, Figure 5D). Instead, splicing of ATM WT
in the presence of increased amounts SF2/ASF did not result
in any pseudoexon inclusion (data not shown).
Relationship between SF2/ASF binding and RNA
secondary structure
When we compared the predicted SF2/ASF-binding motifs
obtained on the entire pseudoexon structure using ESE finder
(Cartegni et al, 2003; Smith et al, 2006), the program pre-
dicted three high scoring SF2/ASF-binding motifs in the
ATMD pseudoexon (Figure 6A, numbered 1–3). Notably,
the first two SF2/ASF motifs (1 and 2) fell on the opposite
sides of the upper stem region of ATMD, whereas the third
SF2/ASF motif (3) fell on the internal loop conformation.
Interestingly, this third motif fell exactly in the region mapped
with the antisense DNA oligos in Figure 5B, suggesting a
relationship between SF2/ASF binding and RNA secondary
structure. A mutation in this sequence was then introduced
that abolished the predicted motif for SF2/ASF binding with-
out affecting the RNA secondary structure (Figure 6B).
In vitro splicing of the ATMD mut SF2 mutant showed almost
complete inhibition of pseudoexon inclusion (Figure 6C). The
expected reduction in SF2/ASF binding efficiency introduced
by this mutation was also confirmed by pull-down analysis
followed by a western blot against this protein (Figure 6D).
Secondary structure changes modulate the binding
of SF2/ASF and additional trans-acting factors on the
pseudoexon sequence
To further explore the relationship between RNA secondary
structure and binding of the trans-acting factors, we gener-
ated two deletion mutants by randomly deleting 20 nt
stretches from the pseudoexon (Figure 7A). In vitro splicing
showed that the two deletion mutants gave contrasting spli-
cing outcomes: the ATMD 15–35 Del showed strong inhibition
of pseudoexon inclusion, whereas the ATMD 40–60 Del mu-
tant displayed pseudoexon inclusion with an even greater
efficiency than ATMD (Figure 7C).
In the case of the 15–35 Del mutant, the puzzling element
was represented by the observation that this mutant showed
almost complete pseudoexon skipping despite the SF2/ASF-
binding site number 3 falling outside the 20 nt deleted region
(Figure 7A). In this case, however, it was observed that the
RNA secondary structure displayed the SF2/ASF number 3
site in a more constricted internal loop compared with the
ATMD structure. Moreover, this 15–35 mutant now displayed
a ‘AGGG’ sequence in a terminal loop conformation that was
earlier concealed in the upper stem region, which closely
matched with a high-affinity hnRNPA1-binding site (Burd and
Dreyfuss, 1994) (Figure 7B).
Second, considering the function of the previously identi-
fied SF2/ASF-binding site, it was unclear why the ATMD
A-like complex










Figure 3 U2snRNP stability at high-salt washings of the ATM WT
and ATMD A-like exon complexes. High-salt washings of the A-like
exon complex assembled on the single exon substrate. Exon com-
plexes that assembled on the MS2-tagged ATM WT and D substrate
were affinity selected on amylose beads after glycerol gradient
ultracentrifugation. The bound complexes were washed with
250 mM NaCl and eluted with maltose. FT lane represents flow
through, W lane is for wash, and E lane for elute. RNAs were
separated and visualized as described above. The autoradiograph of
the same gel is shown below as loading control of the ATM WT and
D pre-mRNAs. Efficiency of recovery has been estimated at 46%
according to CPM counts before and after elution.
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40–60 Del showed better inclusion despite the fact that the
mapped SF2/ASF-binding site was in the 20 nt deleted region.
However, in the case of this mutant, the predicted RNA
secondary structure now displayed the previously unavail-
able SF2/ASF-binding site number 1 in a large terminal loop,
and the SF2/ASF number 2 site in an internal loop
(Figure 7B). Verification of the putative secondary structures
for the 15–35 and 40–60 Del mutants was performed using
RNAse mapping (Supplementary Figure S3).
Finally, to further validate these considerations, we also
performed pull-down analysis to determine SF2/ASF-binding
levels. Notably, SF2/ASF binding to the 40–60 Del mutant
enhanced by at least two times, whereas for the 15–35 Del
mutant it was only slightly reduced (Figure 7D). Moreover, in
keeping with the expectations, the 15–35 Del mutant showed
more than two times increased binding of hnRNPA1 when
compared with both ATMD and 40–60 Del RNAs (Figure 7D).
Sterical hindrance of the ISPE region for SF2/ASF
binding to ATM WT
Considering that the SF2/ASF-binding region is also present
in an open configuration in the ATM WT RNA, it was
interesting to find why the signal of SF2/ASF for the WT
1–65 sequence was reduced with respect to D 1–65 (Figure 4B).
Pull-down analysis confirmed that SF2/ASF binds more effi-
ciently to the ATMD RNA, whereas much weaker binding was
observed to the ATM WT RNA (Figure 8A, lanes 2 and 3,
respectively). It should be noted, however, that the RNA
secondary fold of the ATM WT showed that the U1snRNP
binding at ISPE region falls on the bulge just opposite to the
one occupied by SF2/ASF (Figure 8B). Therefore, U1snRNP
docking at the ISPE would be expected to interfere also with
the SF2/ASF deployment on the opposite side of the internal
loop. To test this hypothesis, we depleted the nuclear extract
with antisense DNA oligo against U1snRNP as described ear-
lier (Raponi et al, 2009) (Supplementary Figure S4). Pull-down
analysis with this extract rescued a significant level of SF2/ASF
binding to the ATM WT sequences, thereby suggesting that
SF2/ASF binding in WT is also modulated by U1snRNP
binding at the ISPE (Figure 8A, lane 1).
Discussion
Normally, inclusion of aberrant exon-like sequences (pseu-
doexons) in mature mRNAs is actively inhibited by the
formation of RNA secondary structures that prevent false
50 and 30ss recognition (Zhang et al, 2005; Schwartz et al, 2009),
by the presence of intrinsic defects in the pseudoexon com-
position (Sun and Chasin, 2000) and by the enrichment of
silencer elements in their vicinity (Fairbrother and Chasin,
2000; Sironi et al, 2004; Zhang and Chasin, 2004).
In particular, very little is known about the trans-acting
factors that bind these silencer elements. So far, research on
this subject has identified several well-known splicing inhi-
bitory factors, such as PTB (Spellman and Smith, 2006;
Sharma et al, 2008). This protein has been found to have
an important function in downregulating the inclusion effi-
ciency of a pathological pseudoexon in NF-1 intron 31,
independently of the activating mutation that creates a very
strong splicing acceptor site (Raponi et al, 2008). This finding
supports the hypothesis that silencer sequences may






































Figure 4 Identification of trans-acting factors that bind the ATM pseudoexon using adipic acid–agarose beads based pull-down and mass-spec
analysis. (A) A scheme of the ATM pseudoexon RNAs used for pull-down analysis is presented. The underlined sequence represents the region
of the pseudoexon used for pull-down analysis that spans from nucleotide 1–45 for ATM WTand ATMD and from nucleotide 32–65 common to
both. (B) Identification of proteins that interact with the ATM WT 1–65 and D 1–65 pseudoexon RNAs. Different synthetic RNAs were
covalently linked to agarose beads and incubated with Hela nuclear extract under splicing conditions. Proteins that remained bound to the
RNAs after washing were separated on 10% SDS–PAGE and detected by Coomassie blue staining. The protein bands identified by mass-spec are
mentioned with arrowheads on the sides of the gel. To obtain a better quantitative picture, the right panel contains western blots against the
U1-70K, U1-A, SF2/ASF, and hnRNPA1 factors (C) Pull-down analysis using RNAs that span from nucleotide 1–45 for ATM WTand ATMD and
from nucleotide 32–65 common to both. Protein bands identified by mass-spec are mentioned with arrowheads on the sides of the gel.
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decrease the probability of randomly activating mutations in
generating potentially harmful pseudoexon inclusion. In ad-
dition, in the case of non-pathological pseudoexon inclu-
sions, such as one described in the a-tropomyosin gene
(Grellscheid and Smith, 2006), specific binding of hnRNP
H/F proteins have been recently found to act as repressors of
this inclusion event (Coles et al, 2009).
One unusual silencer molecule that has been identified in
this search is represented by the U1snRNP, a ribonucleo-
protein complex normally associated in 50ss recognition in
the normal splicing process (Mount et al, 1983). Earlier, our
laboratory has described a strong U1snRNP-binding site that
can inhibit pathological pseudoexon inclusion in intron 20 of
the ATM gene (Figure 1A). Inactivation of this element
through a 4-nt deletion caused pseudoexon inclusion and
occurrence of ataxia telangiectasia in a patient (Pagani et al,
2002). This finding has opened a new research field related to
looking at the U1snRNP factor as a pseudoexon inhibitory
factor. The fact, this new U1snRNP property may not be
limited to a single pseudoexon splicing event comes from the
recent finding that binding of hnRNP E1 and U1snRNP to a
weak 50ss can efficiently inhibit pseudoexon inclusion in the
GH gene preventing the development of Laron syndrome
(Akker et al, 2007). Moreover, examples of 50ss sequences
in splicing suppression have been observed in avian retro-
viral RNA via negative regulator of splicing (Giles and
Beemon, 2005) and the intronic pseudo-50ss in Drosophila P
element transcripts (Siebel et al, 1992). It should also be
mentioned, in parallel, that U1snRNP has already been
reported to be a strong inhibitor of poly(A) addition (and
thus gene expression) when bound to 50ss-like sequences in
the 30 terminal exon of the papilloma virus (Furth et al, 1994),
a property that has been recently exploited to set up a novel
gene silencing methodology (Abad et al, 2008).
In this work, we have further characterized the U1snRNP-
mediated splicing inhibition that is observed in the ATM gene.
Our results have shown that U1snRNP binding to the ATM
ISPE sequence inhibits pseudoexon inclusion for two reasons.
First, previous and recent observations concur with the
opinion that repression of the 30ss in ATM WT is a direct
consequence of U1snRNP binding in correspondence to the
ISPE sequence (Lewandowska et al, 2005; Pastor et al, 2009).
From our experiments, it is now evident that this event
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Figure 5 Mapping of the SF2/ASF-binding site on the ATMD pseudoexon sequence. (A) Schematic representation of 12-mer antisense DNA
oligonucleotides targeting the ATMD pseudoexon sequence. (B) SF2/ASF immunoprecipitation with mAb96 antibody in the absence (lane –) or
presence of these oligonucleotides. The position of the IP complex for SF2/ASF is shown with an arrowhead. (C) In vitro splicing of the ATMD
pre-mRNA using SF2/ASF-depleted Hela Nuclear extract (lane 3) and with mock-depleted extract (lane 4). Schematic diagrams of the spliced
products are shown on the right. Lower panel of (C) contains western blot showing the level of SF2/ASF depletion using the pull-down affinity
procedure together with a tubulin control (D) ATMD pre-mRNA was incubated in either dilute nuclear extract (24%) supplemented with
increasing quantities of recombinant SF2/ASF (lanes 1–3) or standard nuclear extract (48%) (lane 4) under splicing conditions. The quantities
of the SF2/ASF added in mg to the nuclear extract are shown on the top. Schematic diagrams of the spliced products are shown on the right.
Quantification of pseudoexon inclusion levels as determined by densitometric analysis are reported under each figure. Standard deviation
values from three independent experiments are shown.
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which is reflected strongly by the inefficient A complex
formation in the ATM WT RNA.
Second, the presence of the U1snRNP molecule bound to
the ISPE significantly reduces the binding affinity of SF2/ASF
for an enhancer sequence localized far away in the pseudo-
exon sequence but brought in its vicinity by the effects of RNA
secondary structure. In this respect, it is important to note that
these results are totally in keeping with earlier results obtained
for a well-known enhancer sequence in the EDA exon, where
we demonstrated that to have optimal binding
of SR proteins, the binding site needs to be displayed in an
open configuration (Buratti et al, 2004b). These results are also
consistent with recent global studies, which show that en-
hancer and silencer sequences in a wide variety of experi-
mental systems are significantly more single stranded than
expected (Hiller et al, 2007) and that alternative splice site
choice is often modified by the presence of evolutionarily
conserved structures, which favour the use of one splice site
over the competing ones (Shepard and Hertel, 2008). It is also
interesting to note that the SF2/ASF-binding site contains a
(G)AA(G) motif, which was recently found to be enriched in
cryptic exons derived from human transposable elements
(Vorechovsky, 2009). Here, it might also be interesting to
speculate the critical requirement of such a strong enhancer
in the selection of weak 50ss like the ‘gc’ ones, that are
represented by only 0.5–1% of all the 50ss in the human
genome (Thanaraj and Clark, 2001). Our observation that
alternative SF2/ASF-binding sites identified by in silico analy-
sis using ESE finder are not active, suggests that one way to
improve these kinds of programs would be to take local RNA
secondary structure into account. In fact, the bioinformatic
approaches (although a valuable tool) available provide only a
rough approximation to the splicing outcome prediction and
anyone looking for exonic enhancers with the available pro-
grams need to further validate them experimentally
(Hartmann et al, 2008; Houdayer et al, 2008). Furthermore,
the use of linear degenerated sequences in the statistical
approaches without considering their spatial configuration in
the RNA molecule, and the kinetics of RNA synthesis, leave
without explanation why multiple intronic sequences with the
full credentials to be an exon are not included in the final
mRNA molecule.
In conclusion, our results will be useful to better under-
stand how 50ss-like sequences can inhibit splicing, a field of
study that is rapidly emerging due to global analyses of
splicing systems, and have further highlighted the function
ATMΔ




















Figure 6 Correlation between the real and predicted SF2/ASF-binding site with the RNA secondary structure of ATMD. (A) The score matrix of
various SR proteins predicted to bind ATMD RNA as predicted by ESE finder ver3.0. The SF2/ASF predicted motifs are numbered 1–3. The SF2/
ASF-binding site validated experimentally to bind the ATMD pseudoexon overlaps with the predicted motif 3 and is shown by an arrow to fall in
the internal loop conformation. (B) The predicted abolishment of the no. 3 SF2/ASF-binding site in the ATMD mutSF2 mutant. (C) In vitro
splicing and RT–PCR of ATMD and ATMD mutSF2 RNA. Schematic diagrams of the spliced products are shown on the right. Quantification of
pseudoexon inclusion levels as determined by densitometric analysis are reported under each figure. Standard deviation values from three
independent experiments are shown. (D) Western blot pull-down analysis to confirm the abolishment of the SF2/ASF-binding site in the ATMD
mutSF2 substrate in comparison to ATMD. Quantification of SF2/ASF-binding levels as determined by densitometric analysis are reported
under each figure. Standard deviation values from three independent experiments are shown. Ponceau stain of the nitrocellulose membrane is
shown for equal protein loading of the sample.
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of RNA secondary structure in the display of protein/RNA-
binding motifs. Finally, from a therapeutic point of view, our
results show that a suitably modified U1snRNP molecule
targeted to bind a particular pseudoexon sequence may act
as a powerful silencer element. An alternative therapeutic
approach, based on our results, would be to affect the
concentration of SF2/ASF in patient’s cells to decrease pseu-
doexon inclusion. In this respect, it should be noted that
several compounds have been recently developed to achieve
such an aim (Soret et al, 2005). The advantage represented by
such a molecule over more conventional antisense oligo-
nucleotide approaches (Wood et al, 2007) would be to
avoid toxicity, increase the efficiency of nuclear delivery,
and to follow a biocompatible degradation process.
Materials and methods
Constructs carrying the ATMwild-type and mutant sequences
The PY7 plasmid carrying ATM WT and ATMD pseudoexon
sequences have been described in detail elsewhere (Buratti et al,
2007). To obtain ATMD U11, a two-step PCR method was used with
the following primers: 50-tctggccagatatcctttgtgatatatcttc-30 (s) and
50-gaagatatatcacaaaggatatctggccaga-30 (as). Similarly, to obtain the
ATMD mutSF2, the primers used were the following 50-actgatgaggg-
taaagatgccctagatgac-30 (s) and 50-gtcatctagggcatctttaccctcatcagt-30
(as). Finally, to obtain the deletion mutants, ATMD 15–35 Del and
ATMD 40–60 Del the following primers 50-ttatctggccaggtgtgagggtacg
aaggc-30 (s) and 50-gccttcgtaccctcacacctggccagataa-30 (as), 50-cactct
actgatgagcataaggcaagtttt-30 (s) and 50-aaaacttgccttatgctcatcagtagag
tg-30 (as) were used, respectively. To generate the single exon
substrates, the following primer pairs were used: 50-ctaatacgactcac
tatagggcttaactgcaacagtggt-30 (s) and 50-tatcggatccgtaccacagccttaac-30
(as). In parallel, the pMINX–MS2 plasmid was used to generate
DNA fragments containing three MS2 coat protein RNA-binding
sites using the following primers 50-gctgtggtacggatccgatatccgtac-30
(s) and 50-ctatagaactcgactctagag-30 (as), which was fused with the
single exon substrates through overlapping PCR. In addition, ATM
WT and D biexonic constructs were derived from the original
plasmids with the following primers: 50-ctaatacgactcactatagggaata
caagcttgtcgag-30 (s) and 50-ctggtaaaaaacttgccttatgtcat-30 (as).
Spliceosomal complexes and MS2 affinity purification
Splicing complexes were assembled as described earlier (Behzadnia
et al, 2006). Briefly, 10 nM of 32P-labelled capped RNA was
incubated with 40% (v/v) of Hela nuclear extract under splicing
conditions except for final concentration of 46.5 mM KCl. For the
ATP-dependant complexes, at the indicated time, standard splicing
reactions were stopped by addition of heparin to a final concentra-
tion of 0.1 mg/ml, and the incubation was continued for another
5 min. The splicing complexes were separated and visualized using
4% native PAG according to established protocols (Konarska and
Sharp, 1987). Where indicated, a RNA oligonucleotide representing
a 50ss (cuguucagguaaguau, exonic sequence underlined) was added
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% inclusion 20.7±2.1 4±0.2 43.7±2.1
Figure 7 RNA secondary structure can influence splicing by modulating the display of trans-acting factor binding sites. (A) Scheme of the 20 nt
deletions (15–35 and 40–60 Del mutants) made within the ATMD pseudoexon. The ATMD pseudoexon sequence is numbered starting from the
50 end. Boxed sequences correspond to 20 nucleotide deleted region of the ATM pseudoexon. The positions of the GTAA deletion and of the
SF2/ASF-binding site are also shown. (B) Predicted RNA secondary structure of ATMD and of the two deletion mutants. The position of the
trans-acting factors (SF2/ASF and the putative hnRNPA1-binding site) is shown with arcs and brackets. (C) In vitro splicing and RT–PCR
analysis of the ATMD deletion mutants. Schematic diagrams of the spliced products are shown on the right. Quantification of pseudoexon
inclusion levels as determined by densitometric analysis are reported under each figure. Standard deviation values from three independent
experiments are shown. (D) Pull-down analysis of ATMD and the deletion mutants followed by western blotting with mAb96 antibody against
SF2/ASF and a polyclonal hnRNPA1 antibody. Quantification of SF2/ASF-binding levels as determined by densitometric analysis are reported
under each figure. Standard deviation values from three independent experiments are shown. Ponceau stain of the nitrocellulose membrane is
shown for equal protein loading of the sample.
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dried under vacuum and visualized by Phosphorimager (Molecular
Dynamics). Purification of the pre-mRNP complexes were per-
formed as described before (Deckert et al, 2006), except for the
following modifications: the final RNA concentration was 10 nM
and splicing reactions were incubated for 5 min at 301C. The
purification of the complexes was performed at 46.5 mM NaCl
(Buffer G46.5). Ultracentrifugation in a 10–30% glycerol gradient
was performed for 2 h 10 min at 60 K in a sorvall TH660 rotor at 41C.
High-salt washings of amylose bound spliceosomal complexes were
performed with 6 column volumes of 250 mM NaCl. RNA was
separated on an 8.3 M urea/10% (w/v) denaturing polyacrylamide
gel and visualized by silver staining and autoradiography.
Immobilization of RNA on agarose beads and binding assays
The RNAs for bead immobilization were either chemically
synthesized in case of ATM 1–45 WT, ATM 1–45D, and ATM
32–65 RNA oligonucleotides (IDT Technologies) or obtained by
in vitro transcription using T7 RNA polymerase (Stratagene) of PCR-
generated DNA templates. To generate the full-length ATM WT and
D pseudoexon and its various mutants as substrate for pull down,
the following primers were used: 50-taatacgactcactataggga
cagttatctggccaggt-30 (s) and 50-cttgccttatgtcatctaggg-30 (as) except
for the ATMD 40–60 Del where 50-cttgccttatgctcatcagta-30 (as) was
used. RNAs were covalently linked to agarose beads as described
earlier (Buratti et al, 2001) except for few modifications. Buffer D
used at all the washing steps had a final concentration of 50 mM
KCl. A measure of 100 ml of RNA-agarose beads was incubated with
400ml of in vitro splicing reaction (Behzadnia et al, 2006) with final
KCl concentration of 46.5 mM. The proteins bound to the
immobilized RNA were eluted by addition of 60ml of sodium
dodecyl sulfate (SDS)-sample buffer and heated for 5 min at 951C.
Proteins were separated on a 10% SDS–polyacrylamide gel
electrophoresis (PAGE) and analysed by coomassie blue staining,
Ponceau stain of the transferred nitrocellulose membrane, western
blotting, and electronspray mass spectrometry as have been
described in detail elsewhere (Buratti et al, 2004a). To inactivate
U1snRNP, a small oligonucleotide (50-ccaggtaagtat-30, U1AS oligo-
nucleotide) was added to the above reaction mixture at final
concentration of 5 ng/ml and reactions were incubated in the
presence of RNase H (USB). In silico secondary structure predictions
were performed using the mFold program (Zuker, 2003).
IP of SF2/ASF following UV cross-linking and mapping with
12-mer DNA oligos
The ATMD RNA probe was obtained by linearizing the ATMD PY7
plasmid with BamH1 and transcribed with SP6 RNA polymerase
(Promega) in accordance with the standard procedures. UV cross-
linking of (a-32P) UTP-labelled RNAs with commercial HeLa
nuclear extract (C4; Cil Biotech, Belgium) was performed as
described before (Buratti et al, 2004b). To each sample, we added
150ml of IP buffer (20 mM Tris pH¼ 8.0, 300 mM NaCl, 1 mM EDTA,
0.25% NP-40) together with 1 mg of monoclonal antibody (MAb)
and incubated the mixture for 2 h at 41C on a rotator wheel. Anti-
SF2/ASF (mAb96) was purchased from Zymed Laboratories Inc.
After 2 h incubation, we added to each sample 30ml of Protein A/G-
Plus Agarose (Santa Cruz Biotechnologies) and incubated the
mixture at 41C overnight. On the following morning, the beads were
subjected to four washing cycles with 1.5 ml of IP buffer and then
loaded onto an SDS–11% PAGE gel. Gels were run, dried, and then
exposed for 4 to 6 days with a BioMax Screen (Kodak).
In vitro splicing assays
In vitro splicing of capped RNAs was performed as described
elsewhere (Buratti et al, 2007). When necessary, human recombi-
nant SF2/ASF (Jena Bioscience, Germany) was preincubated
with the Hela nuclear extract before the overexpression experiment
as described before (Fu et al, 1992). Conversely, SF2/ASF was
depleted from the Hela nuclear extract using in vitro transcribed
single stranded GAAGAAGAC RNA immobilized on adipic acid
dihydrazide agarose beads (Buratti et al, 2001).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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